ERBB2 and breast carcinoma: Trastuzumab (or its parent murine monoclonal antibody) has been shown to suppress HER2 signaling in HER2-amplified breast cancer cells by blocking the interactions of Src kinase with HER2, thus reducing Src-Y416 phosphorylation and activation [46].